Format

Send to

Choose Destination
Oncotarget. 2015 Jun 10;6(16):14614-24.

Cytogenomic profiling of breast cancer brain metastases reveals potential for repurposing targeted therapeutics.

Author information

1
Department of Oncology, Wayne State University, Detroit, Michigan, USA.
2
Karmanos Cancer Institute, Detroit, Michigan, USA.
3
Department of Neurosurgery, Wayne State University, Detroit, Michigan, USA.
4
Department of Obstetrics/Gynecology, Wayne State University, Detroit, Michigan, USA.
5
Henry Ford Health System, Detroit, Michigan, USA.
6
Department of Pathology, Wayne State University, Detroit, Michigan, USA.

Abstract

Breast cancer brain metastases remain a significant clinical problem. Chemotherapy is ineffective and a lack of treatment options result in poor patient outcomes. Targeted therapeutics have proven to be highly effective in primary breast cancer, but lack of molecular genomic characterization of metastatic brain tumors is hindering the development of new treatment regimens. Here we contribute to fill this void by reporting on gene copy number variation (CNV) in 10 breast cancer metastatic brain tumors, assayed by array comparative genomic hybridization (aCGH). Results were compared to a list of cancer genes verified by others to influence cancer. Cancer gene aberrations were identified in all specimens and pathway-level analysis was applied to aggregate data, which identified stem cell pluripotency pathway enrichment and highlighted recurring, significant amplification of SOX2, PIK3CA, NTRK1, GNAS, CTNNB1, and FGFR1. For a subset of the metastatic brain tumor samples (n = 4) we compared patient-matched primary breast cancer specimens. The results of our CGH analysis and validation by alternative methods indicate that oncogenic signals driving growth of metastatic tumors exist in the original cancer. This report contributes support for more rapid development of new treatments of metastatic brain tumors, the use of genomic-based diagnostic tools and repurposed drug treatments.

KEYWORDS:

brain metastases; breast cancer; copy number variation; oncogenes; targeted therapy

PMID:
25970776
PMCID:
PMC4546491
DOI:
10.18632/oncotarget.3786
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Impact Journals, LLC Icon for PubMed Central
Loading ...
Support Center